ActiCells™ RUO Hypo hiPSCs

Cat.-Nr.: ASE-9550

Description

Accelerate your allogeneic development by starting with a hypoimmunogenic iPSC platform reprogrammed from CD34+ cord blood cells.

  • Hypoimmunogenic — B2M/CIITA double knock-out eliminates expression of HLA Class I and II molecules to avoid recognition by CD8+ and CD4+ T cells
  • Favorable development profile — reprogrammed from CD34+ cord blood cells for reduced immunogenicity and fewer somatic mutations compared to reprogrammed adult cells
  • Excellent differentiation potential — we’ve successfully differentiated the parental line into a number of cell types, including cardiomyocytes, NK cells, T cells, monocytes/macrophages, and endothelial cells
  • Commercialization-ready — genome editing performed with Mad7 technology for clear freedom to operate
  • Genome editing ready — suitable for cell line engineering in our labs or yours

Overview

ActiCells™ RUO Hypo are research-use-only human induced pluripotent stem cells (hiPSCs) engineered to support the development of next-generation allogeneic cell-based medicines. Derived from CD34+ cord blood cells—a neonatal source known for its low mutational burden and reduced immunogenicity—these hiPSCs have been gene-edited to knock out both the β2 microglobulin (B2M) and HLA class II transactivator (CIITA) genes, further minimizing immune recognition through disruption of cell surface expression of MHC class I and II molecules.

The double B2M/CIITA knock-out makes ActiCells™ RUO Hypo hiPSCs an ideal foundation for building hypoimmunogenic, off-the-shelf therapeutic products. The cell line is ready for additional engineering, including the introduction of transgenes that further enhance immune evasion or deliver therapeutic effects. Whether you are designing universal donor cells or testing immune cloaking strategies, these hiPSCs offer a stable and flexible platform for allogeneic development.

Learn about how ActiCells™ RUO Hypo hiPSCs can further be engineered for your project through iPSC gene editing services. Contact us!

The ActiCells™ RUO Hypo hiPSCs will be the research-matching isogenic cell line to the ActiCells™ GMP Hypo hiPSCs which are in development.

Need to insert genes into your hypoimmunogenic iPSCs and want to do it in your own labs? We offer the ActiCells™ RUO TARGATT™ Hypo Knock-in Kit (Cat.# AST-9650) for efficient integration of your therapeutic payload into the H11 safe harbor locus.

Each vial of ActiCells™ RUO Hypo hiPSCs contains 1 x 106 cells. Every lot is tested for viability following recovery from cryopreservation, functional pluripotency (formation of the three germ layers), expression of pluripotency markers (OCT4, SOX2, NANOG, SSEA-4, and TRA-1-60), presence of alkaline phosphatase (AP), STR, sterility, and for the absence of mycoplasma and pathogens (CoA available upon request).

  • SUPPLIER:

    Applied StemCell

  • STATUS:

    In Stock

  • SIZE:

    kit

Overview

  • Species: Human
  • Features: cryopreserved, male
  • iPSC: iPSC control line, iPSC Services

FAQs

Yes, ActiCellsTM RUO Hypo hiPSCs are hypoimmunogenic. The B2M/CIITA double knock-out eliminates expression of HLA Class I and II molecules to avoid recognition by CD8+ and CD4+ T cells.

CD34⁺ cord blood cells exhibit a favorable developmental profile, as they naturally have reduced immunogenicity and fewer somatic mutations compared to reprogrammed adult cells.

ActiCells™ RUO Hypo hiPSCs exhibit broad plasticity and excellent differentiation potential. The parental cell line has been successfully differentiated into multiple cell types, including cardiomyocytes, natural killer (NK) cells, T cells, monocytes/macrophages, and endothelial cells.

Yes, ActiCells™ RUO Hypo hiPSCs are designed with commercialization in mind. Genome editing is performed using Mad7 technology, ensuring a clear freedom-to-operate position and reducing potential IP barriers for downstream applications. MAD7 “is royalty‐free for both academic and commercial research and development use.”1-3

  1. Rojek, J. , Basavaraju, Y. , Nallapareddy, S. , Baumgartner, R. , Schoffelen, S. & Pedersen, L. Mad7: an IP friendly CRISPR enzyme. Authorea. 2022. Available from: 10.22541/au.162863226.68733765/v1
  2. Price MA, Cruz R, Bryson J, Escalettes F, Rosser SJ. Expanding and understanding the CRISPR toolbox for Bacillus subtilis with MAD7 and dMAD7. Biotechnology and Bioengineering. 2020;117(6):1805-1816. doi:10.1002/bit.27312
  3. Mund M, Weber W, Degreif D, Schiklenk C. A MAD7‐based genome editing system for Escherichia coli. Microbial Biotechnology. 2023;16(5):1000-1010. doi:10.1111/1751-7915.14234

Yes, ActiCells™ RUO Hypo hiPSCs are genome-editing ready and ideal for cell line engineering—whether performed in your lab or ours. Their compatibility with common editing workflows makes them a flexible platform for customized research applications. Contact us to learn more about the solutions available through iPSC gene editing services.

Yes! The ActiCells™ RUO TARGATT™ Hypo hiPSC Knock-in Kit (Cat.# AST-9650) enables efficient site-specific integration of your therapeutic payload into the H11 safe harbor locus. It’s designed to support seamless gene insertion workflows directly in your own lab using our hypoimmunogenic ActiCells™ platform.

RELATED PRODUCTS


ActiCells™ RUO TARGATT™ Hypo hiPSC Knock-in Kitreprogrammed CD34+ cord blood cells with reduced immunogenicityTARGATT™ Human Induced Pluripotent Stem Cell (hiPSC) Master Cell Line (Male)...